NICE recommends rivaroxaban (XARELTO®) to prevent blood clots in people who have had a heart attack - NICE 3/25/15
Bayer discloses encouraging data on anticoagulant XARELTO®
Bayer happy with rivaroxaban (XARELTO®) trial results
Efficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fractures.
A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.
Antithrombotic prophylaxis in major orthopaedic surgery: an historical overview and update of current recommendations.
The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery.
Review article: anti-embolism stockings.
Benefit-to-harm ratio of thromboprophylaxis for patients undergoing major orthopaedic surgery. A systematic review.
Prevention of venous thromboembolic disease after total hip and knee arthroplasty.
Complication rates after hip or knee arthroplasty in morbidly obese patients.
New anticoagulants for thromboprophylaxis after total knee arthroplasty.
Rivaroxaban is as efficient and safe as bemiparin as thromboprophylaxis in knee arthroscopy.
Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin.
Prevention of VTE in patients having major orthopedic surgery.
Direct treatment comparison of DAbigatran and RIvaroxaban versus NAdroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: design of a randomised pilot study (DARINA).
Comparative safety and efficacy of antithrombotics in the management of venous thromboembolism after knee or hip replacement surgery: focus on rivaroxaban.
The efficacy and safety of rivaroxaban for venous thromboembolism prophylaxis after total hip and total knee arthroplasty.
Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis.
Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin).
Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.
The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.
Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry.
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty.
Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: a Canadian analysis using the Ontario Ministry of Health Perspective.
Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer’s perspective.
Oral rivaroxaban for symptomatic venous thromboembolism.
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
Rivaroxaban (XARELTO®) National Drug Monograph. June 2012.
Rivaroxaban (XARELTO®) National Drug Monograph Addendum. December 2012.
Rivaroxaban (XARELTO®) Criteria for Use for Treatment of Venous Thromboembolism (VTE) prophylaxis
Rivaroxaban (XARELTO®) Criteria for Use for Stroke Prevention in Nonvalvular Atrial Fibrillation (AF)